Loading...
•
Dec 31, 2024
Edwards Lifesciences Q4 2024 Earnings Report
Key Takeaways
Edwards Lifesciences reported strong Q4 FY24 results with revenue of $1.39 billion, a 9% increase year-over-year. EPS was $0.58, and adjusted EPS was $0.59. Transcatheter Aortic Valve Replacement (TAVR) sales reached $1.04 billion, up 6%, while Transcatheter Mitral and Tricuspid Therapies (TMTT) saw a substantial 88% growth to $105 million. Surgical Structural Heart sales were $244 million, increasing 6%. The company remains confident in its strategic growth areas, with continued expansion in structural heart therapies.
Edwards Lifesciences
Edwards Lifesciences
Edwards Lifesciences Revenue by Segment
Edwards Lifesciences Revenue by Geographic Location
Revenue by Segment
TAVR Revenue
CapyFin.comTMTT Revenue
CapyFin.comSurgical Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comJapan Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Edwards Lifesciences projects continued growth, with Q1 FY25 revenue expected to be between $1.35 billion and $1.43 billion, and adjusted EPS between $0.58 and $0.64. The company anticipates further contributions from structural heart therapies and expects U.S. approval for asymptomatic TAVR by mid-year 2025.
Positive Outlook
- Projected 8-10% constant currency sales growth in 2025
- Adjusted EPS guidance of $2.40-$2.50 for FY25
- Continued strong adoption of TAVR and TMTT products
- Expansion of structural heart therapies in 2026 and beyond
- Stable pricing and competitive positioning across markets
Challenges Ahead
- Lower gross profit margin compared to prior year
- Operating profit margin decreased due to increased investments
- Higher SG&A expenses from strategic acquisitions and transitions
- Expected moderation in R&D spending over time
- Regulatory approval timelines for new indications remain a risk
Revenue & Expenses
Visualization of income flow from segment revenue to net income